Anthracycline-induced cardiotoxicity in breast cancer patients: a 5-year retrospective study in 10 centers

Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis. He was recently at Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current President of the International Cardio-Oncology Society (ICOS),www.IC-OS.org, which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

An assistant professor of medicine at Washington University in St Louis, St. Louis, Missouri, US. Features in 4 videos on Wondr Medical. Jose Alvarez-Cardona generally speaks on Cardio-Oncology, Cardiomyopathy, Cardiotoxicity of Drugs, Oncology Imaging, and Oncology: Webinar.

Joseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the American Journal of Managed Care and was a Senior Corporate Medical Director at Aetna U.S. Healthcare from 1992-2001 where he was responsible for new program development and directed the National Medical Excellence Program. From 1999-2001, he was Co-chairperson of the New Jersey and Michigan Working Groups that established voluntary agreements among the insurers in those states to cover the routine costs of clinical trial participation for cancer patients. He is one of the Founding Editors of Cardio-oncology Journal. He currently is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of Cardio-oncology. He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012 and is one of the founding members of Penn Medicine’s Academy of Master Clinicians. He received the Thomas Force Award in 2020.

Dr. Maria Kristina Cecilia P. Ozaeta-Lorilla is a Diplomat of the Philippine College of Cardiology and Fellows of the Philippine College of Physicians. She is a board-certified cardiologist currently undergoing training in Cardio-Oncology at Makati Medical Center, Philippines, the first formal training center in the country and in Asia which is duly recognized and fully supported by the Council on Cardio-Oncology of the Philippine Heart Association and by the International Cardio-Oncology Society.

Dr. Renato C. Ong Jr. is a Diplomat of the Philippine College of Cardiology and Fellows of the Philippine College of Physicians. He is a board-certified cardiologist currently undergoing training in Cardio-Oncology at Makati Medical Center, Philippines, the first formal training center in the country and in Asia which is duly recognized and fully supported by the Council on Cardio-Oncology of the Philippine Heart Association and by the International Cardio-Oncology Society.